METHODS OF TREATING DISEASE WITH MAGL INHIBITORS

1 . A method for treating dyskinesia in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I′):

wherein:

R 1 is halogen, —OR 3 , —SF 5 , —CN, C 1-6 alkyl optionally substituted by halogen, or —C(O)OR 9 ;

R 2 is —NR 5 R 6 ;

R 3 is selected from H, C 1-6 alkyl, C 1-6 haloalkyl, and C 1-6 aminoalkyl;

R 5 and R 6 , together with the nitrogen to which they are attached, form

(i) a 4-6 membered saturated monocyclic heterocycle; or

(ii) a 7-8 membered bridged heterocyclic ring optionally containing an additional O, N, or S;

wherein the 4-6 membered saturated monocyclic heterocycle is optionally substituted with one or two substituents independently selected from C 1-6 haloalkyl, —C(O)OR 9 , and —NR 9 SO 2 R 8 ; and the 4-6 membered saturated monocyclic heterocycle optionally contains an additional O, N, or S; and

the 7-8 membered bridged heterocyclic ring is optionally substituted with one or two substituents independently selected from halogen, oxo, and C 1-6 alkyl;

each R 8 is independently selected from C 1-6 alkyl; and

each R 9 is independently selected from H and C 1-6 alkyl;

or a pharmaceutically acceptable salt or solvate thereof.

2 . The method of claim 1 , wherein the compound of Formula (I′) is a compound of Formula (III):

wherein:

R 1 is halogen, —OR 3 , —SF 5 , —CN, C 1-6 alkyl optionally substituted by halogen, or —C(O)OR 9 ;

R 2 is —NR 5 R 6 ;

R 3 is selected from H, C 1-6 alkyl, C 1-6 haloalkyl, and C 1-6 aminoalkyl;

R 5 and R 6 , together with the nitrogen to which they are attached, form

(i) a 4-6 membered saturated monocyclic heterocycle; or

(ii) a 7-8 membered bridged heterocyclic ring optionally containing an additional O, N, or S;

wherein the 4-6 membered saturated monocyclic heterocycle is substituted with one or two substituents independently selected from C 1-6 haloalkyl, —C(O)OR 9 , and —NR 9 SO 2 R 8 ; and the 4-6 membered saturated monocyclic heterocycle optionally contains an additional O, N, or S; and

the 7-8 membered bridged heterocyclic ring is optionally substituted with one or two substituents independently selected from halogen, oxo, and C 1-6 alkyl;

each R 8 is independently selected from C 1-6 alkyl; and

each R 9 is independently selected from H and C 1-6 alkyl;

or a pharmaceutically acceptable salt or solvate thereof.

3 . The method of claim 1 or 2 , wherein R 5 and R 6 , together with the nitrogen to which they are attached, form a 4-6 membered saturated monocyclic heterocycle, wherein

the 4-6 membered saturated monocyclic heterocycle is substituted with one substituent selected from C 1-6 haloalkyl, —C(O)OR 9 , and —NR 9 SO 2 R 8 ; and

the 4-6 membered saturated monocyclic heterocycle optionally contains an additional O, N, or S.

4 . The method of claim 3 , wherein R 5 and R 6 , together with the nitrogen to which they are attached, form a 4-6 membered saturated monocyclic heterocycle substituted with one substituent selected from C 1-6 haloalkyl, —C(O)OR 9 , and —NR 9 SO 2 R 8 , wherein the 4-6 membered saturated monocyclic heterocycle is selected from pyrrolidine, piperidine, and morpholine.

5 . The method of claim 4 , wherein R 5 and R 6 , together with the nitrogen to which they are attached, form a 4-6 membered saturated monocyclic heterocycle substituted with one substituent selected from C 1-6 haloalkyl, —C(O)OR 9 , and —NR 9 SO 2 R 8 , wherein the 4-6 membered saturated monocyclic heterocycle is selected from pyrrolidine and piperidine.

6 . The method of claim 1 , wherein R 5 and R 6 , together with the nitrogen to which they are attached, form an unsubstituted 4-6 membered saturated monocyclic heterocycle.

7 . The method of claim 6 , wherein R 5 and R 6 , together with the nitrogen to which they are attached, form an unsubstituted 4-6 membered saturated monocyclic heterocycle, wherein the 4-6 membered saturated monocyclic heterocycle is selected from pyrrolidine, piperidine, and morpholine.

8 . The method of claim 1 or 2 , wherein R 5 and R 6 , together with the nitrogen to which they are attached, form a 7-8 membered bridged heterocyclic ring optionally substituted with one or two substituents independently selected from halogen, oxo, and C 1-6 alkyl.

9 . The method of claim 8 , wherein R 5 and R 6 , together with the nitrogen to which they are attached, form an unsubstituted 7-8 membered bridged heterocyclic ring.

10 . The method of any one of claims 1 - 9 , wherein R 1 is halogen, —SF 5 , or optionally substituted C 1-6 alkyl optionally substituted by halogen.

11 . The method of claim any one of claims 1 - 10 , wherein R 1 is halogen.

12 . The method of claim any one of claims 1 - 10 , wherein R 1 is C 1-6 alkyl optionally substituted by halogen.

13 . The method of claim 12 , wherein R 1 is —CF 3 .

14 . The method of claim 1 , wherein the compound is selected from:

or a pharmaceutically acceptable salt or solvate thereof.

15 . The method of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt or solvate thereof.

16 . The method of any one of claims 1 - 15 , wherein the dyskinesia is levodopa-induced dyskinesia.